Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Current Liabilities (2018 - 2025)

Serina Therapeutics (SER) has disclosed Total Current Liabilities for 8 consecutive years, with $3.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 50.59% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, up 50.59% year-over-year, with the annual reading at $3.6 million for FY2025, 50.59% up from the prior year.
  • Total Current Liabilities hit $3.6 million in Q4 2025 for Serina Therapeutics, down from $8.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $24.5 million in Q2 2023 to a low of $1.4 million in Q4 2023.
  • Historically, Total Current Liabilities has averaged $8.8 million across 5 years, with a median of $8.8 million in 2022.
  • Biggest five-year swings in Total Current Liabilities: crashed 85.98% in 2023 and later soared 321.79% in 2024.
  • Year by year, Total Current Liabilities stood at $9.0 million in 2021, then grew by 12.39% to $10.1 million in 2022, then plummeted by 85.98% to $1.4 million in 2023, then skyrocketed by 67.45% to $2.4 million in 2024, then surged by 50.59% to $3.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for SER at $3.6 million in Q4 2025, $8.8 million in Q3 2025, and $3.6 million in Q2 2025.